June 18, 2018, Farmington, CT - CaroGen, a developer of transformative immunotherapies for infectious disease and cancer, having its initial focus on development of a cure for patients with chronic hepatitis B (CHB), announced that the Company has selected a candidate for advancement into clinical studies. The candidate Virus-Like Vesicle (VLV), known as CARG-101, has many attributes that make it attractive for advancement including expression of three major antigens from Hepatitis B Virus (HBV).

June 12, 2018, Farmington, CT - CaroGen, a developer of transformative immunotherapies for infectious disease and cancer, having its initial focus on development of a cure for patients chronically infected with hepatitis B virus (HBV), today announced that the company has appointed Mr. Harry Penner to serve on the company's board of directors.

April 17, 2017, Farmington, CT - CaroGen Corp, a developer of immunotherapies for HBV as well as other infectious diseases and cancer, announced today an important addition to its Board of Directors and two key senior executive level scientists to its immunotherapy discovery and development team. Bijan Almassian, Ph.D., CaroGen’s CEO stated that, “The addition of these three impressive and experienced individuals, greatly strengthens the CaroGen team and positions the company well with respect to executing on its immunotherapy plans”.

November 8, 2016, Farmington, CT -- The University of Connecticut and CaroGen Corporation, an emerging immunotherapy company, today announced a collaboration aimed at developing a therapeutic vaccine for treatment of patients with colon cancer. CaroGen’s proprietary technology platform will be applied to a specific target studied by UConn Health’s Dr. Kepeng Wang Ph.D., Assistant Professor of Immunology. CaroGen will support this effort with a $70,000 grant to Dr. Wang, and his collaborator Dr. Anthony T. Vella, Ph.D., Professor and Boehringer Ingelheim Chair in Immunology, who will aid in the development of this platform.